Key result
A high comprehensive risk score was an independent prognostic factor of overall and recurrence-free survival in 2,407 patients with colorectal cancer regardless of disease stage.
Why the study?
The comprehensive risk score of the E-PASS predicts postoperative complications and mortality, but its impact on colorectal cancer prognosis remains unclear.
Does the comprehensive risk score (CRS) predict overall and recurrence-free survival in patients undergoing curative colorectal cancer surgery?
Cohort (n=2,407)
Yes
Does the comprehensive risk score (CRS) predict overall and recurrence-free survival in patients undergoing curative colorectal cancer surgery?
The comprehensive risk score (CRS) is a strong independent prognostic factor for overall and recurrence-free survival in patients undergoing curative colorectal cancer surgery, and may help select elderly patients for adjuvant chemotherapy.
OBJECTIVE: To evaluate the prognostic value of the comprehensive risk score (CRS) of the Estimation of Physiologic Ability and Surgical Stress for managing patients with colorectal cancer (CRC) who underwent elective and emergency colorectal cancer surgery with curative intent. SUMMARY BACKGROUND DATA: CRS, which is calculated based on both clinical and surgical factors, is a good predictor of postoperative complications and mortality. However, the impact of CRS in CRC prognosis remains unclear. METHODS: Patients with CRC who underwent curative resection between 2010 and 2019 were retrospectively enrolled in this study. The cohort was divided into the low and high CRS groups. The prognostic value of CRS was evaluated via Cox regression and Kaplan-Meier analyses. The CRS cutoff value was obtained using the Youden index applied to OS curves and have not been validated by any validation cohorts. RESULTS: In total, 2407 patients, including 1359 and 1048 patients with low and high CRS, respectively, were enrolled in this study. Multivariate analysis revealed that a CRS was an independent prognostic factor of overall and recurrence-free survival regardless of disease stage. Furthermore, adjuvant chemotherapy was beneficial for the survival of patients with stage III CRC in both high and low CRS groups; however, the survival benefit was limited in elderly high CRS patients. CONCLUSIONS: CRS was a strong prognostic factor for CRC regardless of disease stage and might be considered as a biomarker for selecting elderly patients who are eligible for adjuvant chemotherapy.
No takes yet. Share an insight, caveat, or question.
Kato et al. (2022) conducted a cohort in Colorectal cancer (n=2,407). High comprehensive risk score (CRS) vs. Low comprehensive risk score (CRS) was evaluated on Overall and recurrence-free survival. A high comprehensive risk score was an independent prognostic factor of overall and recurrence-free survival in 2,407 patients with colorectal cancer regardless of disease stage.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: